A. Charbonnier

发表

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.

J. Bourhis, H. Dombret, D. Olive, 2012, Blood.

Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.

D. Blaise, Wang LiNing, R. Devillier, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.

N. Vey, J. Harlé, M. Ebbo, 2019, Autoimmunity reviews.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

A. Toubert, P. Rousselot, F. Mahon, 2017, Haematologica.

Generation of potent T(h)1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells.

D. Olive, M. Mohty, D. Isnardon, 2002, International immunology.

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study

D. Birnbaum, N. Vey, A. Restouin, 2020, Blood Cancer Journal.

A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia.

F. Bertucci, D. Birnbaum, P. Finetti, 2010, Leukemia research.

Feasibility of High Dose Melphalan (140 mg/m2) and Peripheral Blood Stem Cell Support as Consolidation for Patients over 60 Years with Acute Myeloid Leukemia in First Complete Remission

R. Bouabdallah, D. Blaise, D. Coso, 2003 .

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study

J. Cayuela, P. Cony-Makhoul, H. Bruzzoni-Giovanelli, 2016, Cancer.

Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines

A. Cohen-Solal, A. Cohen, F. Barlesi, 2020, Journal of the American Heart Association.

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

U. Olsson‐Strömberg, T. Brümmendorf, S. Schmidt, 2020, Leukemia.

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

G. Salles, D. Berton‐Rigaud, J. Rey, 2018, Oncotarget.

Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.

P. Morange, P. Suchon, D. Brunet, 2021, Journal de medecine vasculaire.

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients

J. Cayuela, P. Cony-Makhoul, L. Busque, 2021, British journal of haematology.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.

J. Magaud, M. Tulliez, S. Hayette, 2011, Leukemia research.

Improved outcome of patients with low‐ and intermediate‐risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine

B. Esterni, D. Blaise, R. Devillier, 2011, Cancer.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

J. Cayuela, P. Cony-Makhoul, M. Tulliez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive sequential chemotherapy with hematopoietic growth factor support for non‐Hodgkin lymphoma in patients infected with the human immunodeficiency virus

L. Xerri, D. Olive, V. Bardou, 2004, Cancer.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

M. Tulliez, P. Rousselot, F. Mahon, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.

E. Wattel, P. Fenaux, L. Adès, 2014, Leukemia research.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

P. Rousselot, F. Nicolini, L. Roy, 2018, Experimental hematology.

Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications

V. de Lédinghen, A. de Gottardi, D. Valla, 2022, American journal of hematology.

Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias

D. Olive, M. Lafage‐Pochitaloff, D. Sainty, 1999, European journal of immunology.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Andreas Hochhaus, R. Collins, H. Kantarjian, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

M. Tulliez, G. Guillerm, P. Rousselot, 2017, Blood.

Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms

D. Birnbaum, J. Rey, N. Vey, 2018, American journal of hematology.

Monoclonal antibodies and cytomegalovirus infections

R. Bouabdallah, D. Coso, G. Damaj, 2004, European journal of haematology.

Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma.

J. Rey, I. Poizot-Martin, R. Costello, 2003, AIDS.

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

P. Cony-Makhoul, T. Henni, P. Rousselot, 2019, Clinical Cancer Research.

Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

A. Stamatoullas, P. Fenaux, L. Adès, 2012, British journal of haematology.

“One Hour” Rituximab Infusion Is Safe and Improves Patient Care and Outpatient Unit Management.

R. Bouabdallah, D. Coso, J. Rey, 2005 .

Comparison of 60 or 90 mg/m2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics

D. Blaise, C. Récher, R. Devillier, 2015, American journal of hematology.

Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase

P. Fenaux, K. Laribi, G. Miremont-Salamé, 2020, British Journal of Clinical Pharmacology.

Prognostic significance of myelodysplasia‐related changes according to the WHO classification among ELN‐intermediate‐risk AML patients

D. Blaise, R. Devillier, J. Rey, 2015, American journal of hematology.

Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction

D. Blaise, J. Rey, C. Arnoulet, 2012, Leukemia & lymphoma.

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

J. Rey, N. Vey, V. Maisano, 2022, Cancers.

Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

D. Blaise, N. Vey, V. Gelsi-Boyer, 2013, Leukemia & lymphoma.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

J. Cayuela, P. Cony-Makhoul, P. Rousselot, 2018, Cancer.

Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.

D. Blaise, J. Rey, N. Vey, 2017, Clinical lymphoma, myeloma & leukemia.

Y253H mutation appearing in a μ-BCR-ABL (e19a2) CML

S. Olschwang, M. Mozziconacci, O. Gisserot, 2008 .

Early ICU Admission Of Newly Diagnosed Acute Myeloid Leukemia With No Organ Failure

C. Récher, J. Rey, N. Vey, 2013 .

Impact of CRi on the Outcome of Elderly Patients with Untreated Acute Myeloid Leukemia (AML)

D. Coso, J. Rey, N. Vey, 2008 .

Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035

R. Larson, G. Martinelli, J. Reiffers, 2008 .

Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study)

P. Cony-Makhoul, P. Rousselot, F. Mahon, 2022, British journal of haematology.

Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome

D. Blaise, J. Rey, N. Vey, 2020, Annals of Hematology.

Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

E. Tabouret, M. Mozziconacci, A. Charbonnier, 2011, Leukemia research.

Targeting STAT5 Expression Resulted in Molecular Response Improvement in Patients with Chronic Phase CML Treated with Imatinib

J. Cayuela, P. Cony-Makhoul, P. Rousselot, 2012 .

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

H. Dombret, P. Chevallier, M. Béné, 2015, Haematologica.

Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).

D. Olive, F. Orlanducci, J. Rey, 2009 .

HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.

D. Blaise, R. Devillier, S. Harbi, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

D. Blaise, R. Devillier, S. Harbi, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Detection by PCR of avian mycoplasmas from environmental swabs of poultry houses

P. Moalic, A. Charbonnier, B. Chevallier, 2001 .

Human Vγ9Vδ2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts

D. Olive, N. Vey, R. Castellano, 2012, The Journal of Immunology.

Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase.

D. Coso, F. Barlesi, C. Chabannon, 2015, Virology.

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg‐negative and anti‐HBc antibodies‐positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer

R. Bouabdallah, D. Coso, C. Chabannon, 2010, Journal of viral hepatitis.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Philippe Rousselot, J. Reiffers, P. Rousselot, 2010, The Lancet. Oncology.

Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.

J. Reiffers, P. Rousselot, F. Mahon, 2009 .

Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product

B. Esterni, E. Deconinck, D. Coso, 2007, Transfusion.

Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients

P. Rousselot, F. Mahon, F. Guilhot, 2015 .

Reply to J. Richter et al.

J. Cayuela, P. Cony-Makhoul, M. Tulliez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study

J. Reiffers, P. Rousselot, F. Guilhot, 2013 .

Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib

P. Rousselot, F. Mahon, F. Guilhot, 2013 .

Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease

J. Cayuela, P. Cony-Makhoul, M. Tulliez, 2013 .

Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia

B. Esterni, D. Coso, C. Arnoulet, 2007, Cancer.

Means to induce or enhance the immunogenicity of acute myeloid leukemias cells

D. Olive, A. Charbonnier, 1999 .

Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature.

D. Birnbaum, N. Vey, A. Murati, 2008, Leukemia research.

A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).

G. Salles, D. Berton‐Rigaud, J. Rey, 2015 .

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

R. Bouabdallah, D. Blaise, C. Oudin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL

D. Blaise, D. Coso, C. Arnoulet, 2009, Leukemia & lymphoma.

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study

H. Dombret, S. Leprêtre, M. Bernard, 2016, Blood Cancer Journal.

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

R. Larson, H. Dombret, G. Martinelli, 2010, American journal of hematology.

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia

H. Dombret, P. Chevallier, M. Béné, 2017, Haematologica.

Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors

B. Esterni, D. Blaise, D. Coso, 2014, Bone Marrow Transplantation.

Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells

D. Olive, C. Fauriat, F. Orlanducci, 2017, Front. Immunol..

The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute’s Experience

D. Blaise, P. Viens, N. Vey, 2021, Clinical hematology international.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

P. Cony-Makhoul, E. Messas, M. Tulliez, 2016, Bulletin du cancer.

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study.

H. Dombret, M. Bernard, P. Chevallier, 2011, Blood.

Immune reconstitution after blood cell transplantation.

D. Blaise, C. Arnoulet, C. Chabannon, 1997, Hematology and cell therapy.

Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia

D. Blaise, R. Devillier, J. Rey, 2013, Leukemia & lymphoma.

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia

C. Récher, J. Rey, N. Vey, 2017, Leukemia & lymphoma.

Socioeconomic deprivation is associated with decreased survival in patients with acute myeloid leukemia.

J. Rey, J. Boher, A. Charbonnier, 2020, Cancer epidemiology.

Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia

D. Blaise, J. Rey, C. Arnoulet, 2014, Leukemia & lymphoma.

Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre « Stop Imatinib » (STIM) Study

J. Reiffers, P. Rousselot, F. Mahon, 2008 .

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

J. Cortes, M. Deininger, G. Verhoef, 2020 .

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

P. Cony-Makhoul, T. Henni, P. Rousselot, 2022, Haematologica.

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

P. Cony-Makhoul, E. Deconinck, P. Rousselot, 2019, Blood.

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

J. Reiffers, P. Rousselot, F. Mahon, 2011 .

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

J. Cayuela, A. Vekhoff, P. Cony-Makhoul, 2021, Leukemia.

High Relapse Rate of Acute Myeloid Leukemia with Translocation (8;21) or Inversion (16) in Elderly Patients Treated with Conventional Chemotherapy.

D. Coso, N. Vey, M. Mozziconacci, 2007 .

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.

P. Cony-Makhoul, I. Tigaud, A. Delmer, 2023, Leukemia research.

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

T. Brümmendorf, G. Rosti, B. Smith, 2019, Blood.

Prognostic Impact of Mutations in the Nucleophosmin (NPM1) and of the FMS-Related Tyrosine Kinase 3 (FLT3) Genes in Elderly Patients with Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy

S. Olschwang, C. Récher, C. Demur, 2008 .

Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial

J. Cayuela, P. Cony-Makhoul, L. Busque, 2012 .

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

J. Reiffers, P. Rousselot, F. Mahon, 2010 .

Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications

V. de Lédinghen, A. de Gottardi, D. Valla, 2022 .

Preventive Versus Curative Platelet Transfusion Strategies in the Treatment of Acute Myeloid Leukemia Patients: A Comparative Study

X. Thomas, J. Rey, N. Vey, 2014 .

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

J. Cayuela, M. Tulliez, A. Delmer, 2009 .

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

H. Dombret, P. Chevallier, M. Béné, 2015, Haematologica.

Smoothened (Smo) Inhibitor Lde225 Combined With Nilotinib In Patients With Chronic Myeloid Leukemia (Cml) Resistant/Intolerant (R/I) To At Least 1 Prior Tyrosine Kinase Inhibitor: A Phase 1B Study

J. Lipton, O. Ottmann, M. Breccia, 2015 .

A Direct Comparison of High Dose Cytarabine to Combination of Gemtuzumab and High Dose Cytarabine for Acute Myeloid Leukemia Patients in First Relapse Confirmed the Benefit of Gemtuzumab Based Regimens.

D. Blaise, N. Vey, T. Prebet, 2009 .

Two cases of intravascular lymphomatosis disclosing with hypopituitarism.

J. Harlé, N. Schleinitz, A. Charbonnier, 2002, Haematologica.

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

R. Larson, H. Dombret, G. Martinelli, 2010, American journal of hematology.

Improved outcome of patients with low‐ and intermediate‐risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine

B. Esterni, D. Blaise, R. Devillier, 2011, Cancer.

Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

H. Dombret, P. Chevallier, M. Béné, 2016 .

Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.

Norman Abbou, V. Maisano, G. Venton, 2024, Leukemia research.